AGC Biologics, a global Contract Development and Manufacturing Organisation for Biopharmaceuticals, has collaborated with Japan-based Takara Bio, it was reported on Thursday.
The firms are collaborating on a COVID-19 prophylaxis DNA vaccine, with AGC Biologics manufacturing the plasmid DNA intermediate for the vaccine. The vaccine will be produced based on Osaka University and AnGes Inc's expertise of developing plasmid DNA products.
AGC Biologics CBO, Mark Womack, said, 'AGC Biologics is delighted to be working with Takara Bio on a project that will make a big difference for countless people. Our organisation looks forward to partnering with Takara Bio to successfully fight this global threat.'
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses